Updates are available Correction dated 2025-01-09
Click to view Correction: https://doi.org/10.1038/s41467-025-55864-4
-
Authors
Huré, Jean-Baptiste
Foucault, Louis
Ghayad, Litsa Maria
Marie, Corentine
Vachoud, Nicolas https://orcid.org/0009-0005-5280-7126
Baudouin, Lucas https://orcid.org/0000-0001-6772-8168
Azmani, Rihab
Ivljanin, Natalija
Arevalo-Nuevo, Alvaro https://orcid.org/0009-0007-0803-1177
Pigache, Morgane
Bouslama-Oueghlani, Lamia
Chemelle, Julie-Anne
Dronne, Marie-Aimée
Terreux, Raphaël https://orcid.org/0000-0003-1243-7413
Hassan, Bassem https://orcid.org/0000-0001-9533-4908
Gueyffier, François
Raineteau, Olivier
Parras, Carlos
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-17-CE16-0009, ANR-22-CE17-0029)
Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques (ARSEP-1284)
- License Information
-
More Information
Article History
Received: 3 May 2023
Accepted: 25 October 2024
First Online: 13 November 2024
Change Date: 9 January 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-55864-4
Competing interests
: Jean-Baptiste Hure, Carlos Parras, Olivier Raineateau, and Louis Foucault are inventors in the patent entitled ‘Organic molecules for 1312 treating myelin pathologies’, published on September 28th, 2023 (WO2023180474) that is based on most of the data published in this study. Patent applicants: ICM - Paris Brain Institute, INSERM, CNRS, AAPHP, Sorbonne Université, Université Claude Bernard Lyon 1. The other authors declare no competing interests.
